Strata Oncology, Inc. (“Strata”), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer. The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit.
Strata Select is available immediately for clinical use and is the first immunotherapy biomarker algorithm to be covered by Medicare across solid tumors meeting specified coverage criteria. The diagnostic test received a positive coverage determination from Palmetto MolDX under the policy “Next-Generation Sequencing for Solid Tumors.”
“Strata Oncology’s mission is to provide oncologists and patients with precise, actionable insights for more personalized and effective cancer treatments,” said Dan Rhodes Ph.D., co-founder and CEO of Strata Oncology. “Medicare coverage for our groundbreaking Strata Select test marks a significant milestone in our pursuit to deliver precision immunotherapy, empowering oncologists to make better-informed treatment decisions and enhance patient outcomes.”
Read more here.